|
1
|
The definition and classification of dry
eye disease, . Report of the Definition and Classification
Subcommittee of the International Dry Eye WorkShop (2007). Ocul
Surf. 5:75–92. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marshall LL and Roach JM: Treatment of dry
eye disease. Consult Pharm. 31:96–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
No authors listed, . The epidemiology of
dry eye disease: Report of the Epidemiology Subcommittee of the
International Dry Eye WorkShop (2007). Ocul Surf. 5:93–107. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rapoport Y, Singer JM, Ling JD, Gregory A
and Kohanim S: A comprehensive review of sex disparities in
symptoms, pathophysiology, and epidemiology of dry eye syndrome.
Semin Ophthalmol. 31:325–336. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miljanović B, Dana R, Sullivan DA and
Schaumberg DA: Impact of dry eye syndrome on vision-related quality
of life. Am J Ophthalmol. 143:409–415. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
American Academy of Ophthalmology
Cornea/External Disease Panel, . Dry Eye Syndrome Preferred
Practive Pattern Guidelines. American Academy of Ophthalmology; San
Francisco, CA: 2013
|
|
7
|
Arakawa T, Higuchi K, Fujiwara Y, Watanabe
T, Tominaga K, Sasaki E, Oshitani N, Yoshikawa T and Tarnawski AS:
15th anniversary of rebamipide: Looking ahead to the new mechanisms
and new applications. Dig Dis Sci. 50 (Suppl 1):S3–S11. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Higuchi K, Arakawa T, Nebiki H, Uchida T,
Fujiwara Y, Ando K, Yamasaki K, Takaishi O, Fukuda T, Kobayashi K
and Kuroki T: Rebamipide prevents recurrence of gastric ulcers
without affecting Helicobacter pylori status. Dig Dis Sci.
43:99S–106S. 1998.PubMed/NCBI
|
|
9
|
Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H
and Morita S: Gastric mucosal protection by OPC-12759, a novel
antiulcer compound, in the rat. Eur J Pharmacol. 142:23–29. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yoshikawa T, Naito Y, Tanigawa T and Kondo
M: Free radical scavenging activity of the novel anti-ulcer agent
rebamipide studied by electron spin resonance.
Arzneimittelforschung. 43:363–366. 1993.PubMed/NCBI
|
|
11
|
Naito Y, Yoshikawa T, Tanigawa T, Sakurai
K, Yamasaki K, Uchida M and Kondo M: Hydroxyl radical scavenging by
rebamipide and related compounds: Electron paramagnetic resonance
study. Free Radic Biol Med. 18:117–123. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Urashima H, Okamoto T, Takeji Y, Shinohara
H and Fujisawa S: Rebamipide increases the amount of mucin-like
substances on the conjunctiva and cornea in the
N-acetylcysteine-treated in vivo model. Cornea. 23:613–619. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rios JD, Shatos M, Urashima H, Tran H and
Dartt DA: OPC-12759 increases proliferation of cultured rat
conjunctival goblet cells. Cornea. 25:573–581. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rios JD, Shatos MA, Urashima H and Dartt
DA: Effect of OPC-12759 on EGF receptor activation, p44/p42 MAPK
activity, and secretion in conjunctival goblet cells. Exp Eye Res.
86:629–636. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takeji Y, Urashima H, Aoki A and Shinohara
H: Rebamipide increases the mucin-like glycoprotein production in
corneal epithelial cells. J Ocul Pharmacol Ther. 28:259–263. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Itoh S, Itoh K and Shinohara H: Regulation
of human corneal epithelial mucins by rebamipide. Curr Eye Res.
39:133–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Arakaki R, Eguchi H, Yamada A, Kudo Y,
Iwasa A, Enkhmaa T, Hotta F, Mitamura-Aizawa S, Mitamura Y, Hayashi
Y, et al: Anti-inflammatory effects of rebamipide eyedrop
administration on ocular lesions in a murine model of primary
Sjögren's syndrome. PLoS One. 9:e983902014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kinoshita S, Awamura S, Oshiden K,
Nakamichi N, Suzuki H and Yokoi N; Rebamipide Ophthalmic Suspension
Phase II Study Group, : Rebamipide (OPC-12759) in the treatment of
dry eye: A randomized, double-masked, multicenter,
placebo-controlled phase II study. Ophthalmology. 119:2471–2478.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kinoshita S, Oshiden K, Awamura S, Suzuki
H, Nakamichi N and Yokoi N; Rebamipide Ophthalmic Suspension Phase
3 Study Group, : A randomized, multicenter phase 3 study comparing
2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the
treatment of dry eye. Ophthalmology. 120:1158–1165. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koh S, Inoue Y, Sugmimoto T, Maeda N and
Nishida K: Effect of rebamipide ophthalmic suspension on optical
quality in the short break-up time type of dry eye. Cornea.
32:1219–1223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kinoshita S, Awamura S, Nakamichi N,
Suzuki H, Oshiden K and Yokoi N; Rebamipide Ophthalmic Suspension
Long-term Study Group, : A multicenter, open-label, 52-week study
of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with
dry eye. Am J Ophthalmol. 157:576–583.e1. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arimoto A, Kitagawa K, Mita N, Takahashi
Y, Shibuya E and Sasaki H: Effect of rebamipide ophthalmic
suspension on signs and symptoms of keratoconjunctivitis sicca in
Sjögren syndrome patients with or without punctal occlusions.
Cornea. 33:806–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamane M, Ogawa Y, Fukui M, Kamoi M,
Saijo-Ban Y, Yaguchi S, Mukai S, Kawakita T, Simmura S and Tsubota
K: Long-term rebamipide and diquafosol in two cases of
immune-mediated dry eye. Optom Vis Sci. 92:S25–S32. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kato K, Miyake K, Kondo N, Asano S, Takeda
J, Takahashi A, Takashima Y and Kondo M: Conjunctival goblet cell
density following cataract surgery with diclofenac versus
diclofenac and rebamipide: A randomized trial. Am J Ophthalmol.
181:26–36. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chauhan SK, El Annan J, Ecoiffier T, Goyal
S, Zhang Q, Saban DR and Dana R: Autoimmunity in dry eye is due to
resistance of Th17 to Treg suppression. J Immunol. 182:1247–1252.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Barabino S, Shen L, Chen L, Rashid S,
Rolando M and Dana MR: The controlled-environment chamber: A new
mouse model of dry eye. Invest Ophthalmol Vis Sci. 46:2766–2771.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang C, Li K, Yang Z, Wang Y and Si H:
The effect of the aqueous extract of Bidens pilosa L. on androgen
deficiency dry eye in rats. Cell Physiol Biochem. 39:266–277. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sanchis-Gimeno JA, Lleó-Pérez A, Alonso L,
Rahhal MS and Martínez-Soriano F: Reduced corneal thickness values
in postmenopausal women with dry eye. Cornea. 24:39–44. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fabiani C, Barabino S, Rashid S and Dana
MR: Corneal epithelial proliferation and thickness in a mouse model
of dry eye. Exp Eye Res. 89:166–171. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Garg A and Zhang X: Lacrimal gland
development: From signaling interactions to regenerative medicine.
Dev Dyn. 246:970–980. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sullivan DA: Sex hormones and Sjögren's
syndrome. J Rheumatol. (Suppl 50):S17–S32. 1997.
|
|
33
|
Stern ME and Pflugfelder SC: Inflammation
in dry eye. Ocul Surf. 2:124–130. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stern ME, Siemasko KF, Gao J, Calonge M,
Niederkorn JY and Pflugfelder SC: Evaluation of ocular surface
inflammation in the presence of dry eye and allergic conjunctival
disease. Ocul Surf. 3:S161–S164. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stern ME, Beuerman RW, Fox RI, Gao J,
Mircheff AK and Pflugfelder SC: The pathology of dry eye: The
interaction between the ocular surface and lacrimal glands. Cornea.
17:584–589. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Stern ME, Gao J, Siemasko KF, Beuerman RW
and Pflugfelder SC: The role of the lacrimal functional unit in the
pathophysiology of dry eye. Exp Eye Res. 78:409–416. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pflugfelder SC, Corrales RM and de Paiva
CS: T helper cytokines in dry eye disease. Exp Eye Res.
117:118–125. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Song XJ, Li DQ, Farley W, Luo LH,
Heuckeroth RO, Milbrandt J and Pflugfelder SC: Neurturin-deficient
mice develop dry eye and keratoconjunctivitis sicca. Invest
Ophthalmol Vis Sci. 44:4223–4229. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang X, Chen W, De Paiva CS, Corrales RM,
Volpe EA, McClellan AJ, Farley WJ, Li DQ and Pflugfelder SC:
Interferon-γ exacerbates dry eye-induced apoptosis in conjunctiva
through dual apoptotic pathways. Invest Ophthalmol Vis Sci.
52:6279–6285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
de Paiva CS, Schwartz CE, Gjörstrup P and
Pflugfelder SC: Resolvin E1 (RX-10001) reduces corneal epithelial
barrier disruption and protects against goblet cell loss in a
murine model of dry eye. Cornea. 31:1299–1303. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ohguchi T, Kojima T, Ibrahim OM, Nagata T,
Shimizu T, Shirasawa T, Kawakita T, Satake Y, Tsubota K, Shimazaki
J, et al: The effects of 2% rebamipide ophthalmic solution on the
tear functions and ocular surface of the superoxide dismutase-1
(sod1) knockout mice. Invest Ophthalmol Vis Sci. 54:7793–7802.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bettelli E, Oukka M and Kuchroo VK:
T(H)-17 cells in the circle of immunity and autoimmunity. Nat
Immunol. 8:345–350. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cooke A: Th17 cells in inflammatory
conditions. Rev Diabet Stud. 3:72–75. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bettelli E, Carrier Y, Gao W, Korn T,
Strom TB, Oukka M, Weiner HL and Kuchroo VK: Reciprocal
developmental pathways for the generation of pathogenic effector
TH17 and regulatory T cells. Nature. 441:235–238. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
De Paiva CS, Hwang CS, Pitcher JD III,
Pangelinan SB, Rahimy E, Chen W, Yoon KC, Farley WJ, Niederkorn JY,
Stern ME, et al: Age-related T-cell cytokine profile parallels
corneal disease severity in Sjögren's syndrome-like
keratoconjunctivitis sicca in CD25KO mice. Rheumatology (Oxford).
49:246–258. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pitcher JD III, De Paiva CS, Pelegrino FS,
McClellan AJ, Raince JK, Pangelinan SB, Rahimy E, Farley WJ, Stern
ME, Li DQ, et al: Pharmacological cholinergic blockade stimulates
inflammatory cytokine production and lymphocytic infiltration in
the mouse lacrimal gland. Invest Ophthalmol Vis Sci. 52:3221–3227.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
De Paiva CS, Chotikavanich S, Pangelinan
SB, Pitcher JD III, Fang B, Zheng X, Ma P, Farley WJ, Siemasko KF,
Niederkorn JY, et al: IL-17 disrupts corneal barrier following
desiccating stress. Mucosal Immunol. 2:243–253. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dohlman TH, Chauhan SK, Kodati S, Hua J,
Chen Y, Omoto M, Sadrai Z and Dana R: The CCR6/CCL20 axis mediates
Th17 cell migration to the ocular surface in dry eye disease.
Invest Ophthalmol Vis Sci. 54:4081–4091. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang X, Volpe EA, Gandhi NB, Schaumburg
CS, Siemasko KF, Pangelinan SB, Kelly SD, Hayday AC, Li DQ, Stern
ME, et al: NK cells promote Th-17 mediated corneal barrier
disruption in dry eye. PLoS One. 7:e368222012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sadrai Z, Stevenson W, Okanobo A, Chen Y,
Dohlman TH, Hua J, Amparo F, Chauhan SK and Dana R: PDE4 inhibition
suppresses IL-17-associated immunity in dry eye disease. Invest
Ophthalmol Vis Sci. 53:3584–3591. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Min HK, Kim JK, Lee SY, Kim EK, Lee SH,
Lee J, Kwok SK, Cho ML and Park SH: Rebamipide prevents peripheral
arthritis and intestinal inflammation by reciprocally regulating
Th17/Treg cell imbalance in mice with curdlan-induced
spondyloarthritis. J Transl Med. 14:1902016. View Article : Google Scholar : PubMed/NCBI
|
